Evidence map›Paper›PMID 37425980›Full record

ArticleOncoTargets and therapy2023

Exploring the Association Between PRC2 Genes Variants and Lung Cancer Risk in Chinese Han Population.

Min Gao, Yongwen Li, Hua Huang, Yaguang Fan, Ruifeng Shi, Lianchun Su, Chen Chen, Xuanguang Li, Guangsheng Zhu, Di Wu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Min Gao *Department of Thoracic Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010010, People's Republic of China.
Yongwen Li *Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.ORCID 0000-0001-6102-2949
Hua Huang *Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China.
Yaguang FanTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Ruifeng ShiDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China.
Lianchun SuDepartment of Thoracic Surgery, First Affiliated Hospital of Shihezi University School of Medicine, Shihezi, People's Republic of China.
Chen ChenTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Xuanguang LiDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China.
Guangsheng ZhuDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China.
Di WuDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China.
Peijun CaoDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China.
Hongyu LiuTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Jun ChenTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Shirong KangDepartment of Thoracic Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010010, People's Republic of China.ORCID 0000-0002-5424-0021
Tianjin Medical University General Hospital · CNInner Mongolia Medical University · CNShihezi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Genetic susceptibilities play a large role in the pathogenesis of lung cancer (LC). The polycomb repressive complex 2 (PRC2) is a conserved chromatin-associated complex that represses gene expression and is crucial for proper organismal development and gene expression patterns. Despite PRC2 dysregulation has been observed in various human cancers, the relationship between PRC2 genes variants and lung cancer risk remains largely unexplored. Methods: To investigate the association between single nucleotide polymorphisms (SNPs) in PRC2 genes and the risk of developing LC, we genotyped blood genomic DNA from 270 LC patients and 452 healthy individuals of Chinese Han ethnicity using the TaqMan™ genotyping technique. Results: We found that rs17171119T>G(adjusted odds ratio (OR) = 0.662, 95% CI: 0.467-0.938, Conclusion: This study provides evidence that allelic variants in EZH2, EED, and RBBP4 may act as protective factors against LC development and could serve as genetic markers associated with susceptibility to LC.

Indexed as

lung cancersingle nucleotide polymorphismthe polycomb repressive complex 2

Identifiers

PMID37425980
PMCPMC10328106
OpenAlexW4382940014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.